

1 **Impacts of 203/204: RG>KR mutation in the N protein of SARS-CoV-2**

2 Majid Vahed,^a Tess M Calcagno,^b Elena Quinonez,^b, and Mehdi Mirsaeidi^{d*}

3 ^aDivision of Pulmonary and Critical Care, University of Miami, FL, USA

4 ^bDepartment of Medicine, University of Miami, Miami, FL, USA

5 Running Head: N protein of SARS-CoV-2 (RG>KR)

6 * Corresponding Author to whom requests for reprints should be addressed

7 Mehdi Mirsaeidi MD, 1600 NW 10th Ave # 7072B, Miami, Florida, USA 33136;

8 msm249@med.miami.edu

9 Conflicts of Interest: Authors reports not competing interest

10 Author contributions: Conceptualization (MM), Methodology (MV, EQ, MM), Writing (MV,
11 TC, MM), Preparation (MV, EQ, TC), Reviewing & Editing (MV, TC, MM)

12

13 Word Count Abstract: 148

14 Word Count Text: 3,778

15

16

17

18

19

20 **Abstract**

21 We present a structure-based model of phosphorylation-dependent binding and sequestration
22 of SARS-CoV-2 nucleocapsid protein and the impact of two consecutive amino acid changes
23 R203K and G204R. Additionally, we studied how mutant strains affect HLA-specific antigen
24 presentation and correlated these findings with HLA allelic population frequencies. We discovered
25 RG>KR mutated SARS-CoV-2 expands the ability for differential expression of the N protein
26 epitope on Major Histocompatibility Complexes (MHC) of varying Human Leukocyte Antigen
27 (HLA) origin. The N protein LKR region K203, R204 of wild type (SARS-CoVs) and (SARS-
28 CoV-2) observed HLA-A*30:01 and HLA-A*30:21, but mutant SARS-CoV-2 observed HLA-
29 A*31:01 and HLA-A*68:01. Expression of HLA-A genotypes associated with the mutant strain
30 occurred more frequently in all populations studied.

31 **Importance**

32 The novel coronavirus known as SARS-CoV-2 causes a disease renowned as 2019-nCoV
33 (or COVID-19). HLA allele frequencies worldwide could positively correlate with the severity of
34 coronavirus cases and a high number of deaths.

35

36

37

38

39

40 **1. Introduction**

41 A major outbreak of a novel coronavirus isolated in china called SARS-CoV2 leads to the
42 global declaration of a worldwide pandemic (1). The novel coronavirus known as SARS-CoV2
43 causes a disease renowned as 2019-nCoV (or COVID-19) (1-3). Sequencing of the viral genome
44 and characterization of immunogenic viral proteins has been crucial for understanding the virus
45 and creating targeted vaccinations and treatments. Additionally, wide variation in the clinical
46 presentation of COVID-19 ranging from an asymptomatic presentation to disabling multi-organ
47 failure has led to the study of differential host-pathogen interaction specifically relating to
48 population-based Human Leukocyte antigen (HLA) allele frequencies (4, 5).

49 SARS-CoV2 is an RNA virus and structurally contains 16 open reading frames (ORFs).
50 ORF1a express 11 nonstructural proteins (Nsps) from Nsp1 to Nsp11, with the genes of ORF1b
51 expressing proteins from Nsp12 to Nsp16 (6, 7). Major structural proteins including Spike (S),
52 envelope (E), membrane (M) and nucleocapsid (N) proteins are encoded by other ORFs. The N
53 proteins of SARS-CoV are highly basic structural proteins localized in the cytoplasm and the
54 nucleolus of *Trichoplusia ni* BT1 Tn 5B1-4 cells (8). Previous studies have indicated the N
55 proteins of other coronaviruses are extensively phosphorylated and bound to viral RNA to form a
56 helical ribonucleoprotein (RNP) that comprises the viral core structure (9). Recently, mutations in
57 N segment of SARS-CoV2 have been reported (10). Two replacements in positions R203K and
58 G204R of N proteins have been found in several countries, but their potential effects in the protein
59 structure have not been discussed.

60

61 We present a structure-based model of phosphorylation-dependent binding and
62 sequestration of SARS-CoV-2 nucleocapsid protein and the impact of two consecutive amino
63 acid changes R203K and G204R. Additionally, we studied how mutant strains affect HLA-
64 specific antigen presentation and correlated these findings with HLA allelic population
65 frequencies.

66 **2. Results**

67 *2.1. Sequence Alignments and Clustering of LKR of CoVs N-protein*

68 ClustalW multiple sequence alignment was employed to align the LKR (68 nucleotides
69 long) of CoV N protein aligned for bat/pangolin models and human models SARS-
70 COVs/MERS-COV. Notably, The Gly at position 204 is conserved among the closely related
71 coronaviruses Bat coronavirus pangolin, SARS-CoV, and SARS-CoV-2, but variable for SARS-
72 CoV2n (fig. 1(a)). The clustering trees of coronavirus are displayed in figure 1 (b). Sequence
73 alignments suggested that other coronavirus N proteins might share the same structural
74 organization based on intrinsic disorder predictor profiles and secondary structure predictions
75 (Fig. 2).

76 *2.2. Calculation of N-protein LKR Residue Energies*

77 A plot of N-proteins residues indicates the local model quality by plotting knowledge-based
78 energies as a function of an amino acid sequence position. A detailed energy calculation of wild
79 and mutant types revealed residues 203/204 are located in the highest energy level area (Fig. 3).
80 The mutant type showed slightly high free energy at residues 203/204 a.a. KR compared to the
81 wild type; suggesting enhanced structural flexibility and increased the tendency for the formation
82 of a coil or a bend in the secondary structure. The relative orientation of NTD and CTD, as well

83 as the conformations of the disordered regions (N-arm, LKR, and C-tail), are drawn randomly to
84 reflect the dynamic nature of the N protein (Fig. 3)

85 *2.3. Calculation of Putative Phosphorylation Sites*

86 We also analyzed predictable phosphorylation sites of N-protein by employing the NetPhos
87 3.1 server (<http://www.cbs.dtu.dk/services/NetPhos/>, accessed on 14 Sep 2020). The linker
88 region of SARS-CoV N-protein (LKR) contains a Ser/Arg-rich region with a high number of
89 putative phosphorylation sites (a.a. 172–206). The sites of contiguous amino acid changes of
90 203R>K and 204G>R are located in the SR-rich region which is known to be intrinsically
91 disordered. We predicted a nonspecific kinase phosphorylation site at Ser202 and a specific
92 CDK5, RSK, and GSK3 phosphorylation sites at Ser206, all of which are close to the RG>KR
93 mutation (Fig. 4). When Ser202/206 and Thr205 are phosphorylated, charge neutralization of
94 the nearby positively charged sidechains likely takes place. The G204R mutation decreases the
95 conformational entropy of neutralization by increasing the positive charge in the vicinity of
96 negatively charged P-Ser202/205 phosphate groups (Fig. 5).

97 *2.4 Protein Localization*

98 Subcellular localization of the N-protein was predicted using the DeepLoc 1.0 neural network
99 algorithm. The resultant values of 0.861 and 0.913 obtained for wild and mutant N protein
100 respectively suggest the protein is predominantly found in the nucleus (Fig. 6 a,b). The N-protein
101 position prediction graph (Fig.6,c,d) confirmed a long peak in mutation areas K203 and R204,
102 defined based on SARS-CoV-2 data.

103 *2.5 Identification of N-protein B-cell epitopes*

104 We used the Immune Epitope Database (IEDB) to determine linear B-cell hosted epitopes
105 utilizing the incorporated Chou & Fasman Beta-Turn prediction module threshold 1.07. We

106 supplied the FASTA sequence of the targeted protein as an input assuming all default parameters.
107 LKR (a.a.170-206) region of N-protein shown significant antigenic epitopes with potential binding
108 to B lymphocytes cells (Fig. 7). IEDB software also predicted epitopes based on N-protein
109 conformation and residue exposure, and independently graphed a broad peak in mutation areas
110 K203 and R204, the likely epitope regions defined based on SARS-CoV-2 data (Fig. S2).

111 *2.6 Identification of T-cell epitopes*

112 We found that MHC polymorphism typically results in differential MHC epitope
113 recognition within the N-protein LKR K203 R204 region of wild type (SARS-CoV-2) as
114 compared to mutant (SARS-CoV2). Wild type (SARS-CoV-2) observed HLA-A*30:01 and HLA
115 31:01 predictions, but mutant SARS-CoV-2 observed HLA-A*31:01 and HLA-A*68:01
116 predictions (Table 1,2). The frequency of HLA class I representation within South American,
117 Japanese, and Iranian populations was recorded for both wild type and mutant strains. HLA class
118 I molecules associated with mutant strains occurred more frequently in all three population groups,
119 with the most significant increase seen in the South American population (18.38% in wild type
120 versus 28.25% in the mutant).

121 **3. Discussion**

122 Variations in Host Human Leukocyte Antigen (HLA) gene expression can influence
123 antigenic presentation of coronavirus epitopes. The Nucleocapsid (N) proteins of many
124 coronaviruses are highly immunogenic epitopes expressed abundantly during infection. Using
125 genome sequencing and prediction models, we characterized a mutation in the N-protein which
126 affected the viral structure, function, and immunogenicity.

127 In the case of SARS-CoV N protein, previous studies have demonstrated that there are three
128 intrinsically disordered regions (IDRs) (residues 1–44, 182–247, and 366–422) which modulate
129 the RNA-binding activity of the N-terminal domain (NTD) and the C-terminal domain (CTD) (11).

130 The middle IDR, which we coined the linker region of SARS-CoV N protein (a.a. 182–247) LKR,
131 and C-terminal IDR have both been implicated in the oligomerization of the N protein (12, 13).
132 Five a.a variations at position 203 (R203K/M/S/I/G) within the SR-rich domain have been
133 studied of the five variations, substitution R203K occurred most frequently in 68.09% of the
134 mutated strains globally followed by the substitution G204R found in 67.94% mutated
135 strains of the SARS-CoV-2 [19].

136 We identified phosphorylation sites in close proximity to the 203/204: RG>KR mutation and
137 modeled the mutation's potential role in the alteration of protein structure and favorable
138 electrostatic interaction between positively charged Arg and the negatively charged P-
139 Ser202/205. A decrease in structural instability could contribute to a potential increase in
140 immunogenicity of the mutant variant.

141 The N protein wild type is known to be a representative antigen for the T-cell response in
142 a vaccine setting, inducing SARS-specific T-cell proliferation and cytotoxic activity (14, 15).
143 We discovered RG>KR mutated SARS-CoV-2 expands the ability for differential expression of
144 the N protein epitope on Major Histocompatibility Complexes (MHC) of varying Human
145 Leukocyte Antigen (HLA) origin. Specifically, the N protein LKR region K203 R204 of wild
146 type (SARS-CoVs) and (SARS-CoV-2) observed HLA-A*30:01 and HLA-A*30:21, but mutant
147 SARS-CoV-2 observed HLA-A*31:01 and HLA-A*68:01. Expression of HLA-A genotypes
148 associated with the mutant strain occurred more frequently in all populations studied (South
149 American, Japanese, and Iranian) with the most significant increase in frequency seen in the
150 South Americans.

151 Major MHC-I molecules play a key role in the recognition of intracellular pathogens.
152 HLA-A*31:01, associated with mutant and wild type strains is reported to be linked with
153 carbamazepine (CBZ)-induced severe cutaneous adverse reactions (SCAR), including medicine
154 reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS),
155 and toxic epidermal necrolysis (TEN) (16). HL-A*68:01 was only associated with the mutant
156 strain in our analysis. Two previous independent studies linked the HLA-A*68:01 allele, which
157 is expressed at 5.2–25% allele frequency, with severe influenza disease during the 2009 influenza
158 pandemic (17, 18).

159 The frequency of the HLA-A*68:01 allomorph is high among the indigenous populations
160 globally including Southern America (<http://www.allelefreqencies.net>) and Australia (19, 20).
161 HLA-A*68:01 is at low levels in most of SE Asia, particularly the indigenous populations
162 reflected by low levels along the West Pacific Rim including Japan (19). If HLA-A*68:01
163 expression correlates with the manifestation of a more severe illness course, HLA-A*68:01
164 allele frequencies worldwide could positively correlate with the severity of coronavirus cases
165 and a high number of deaths seen in south American countries like Brazil (21). On the other hand,
166 low HLA-A*68:01 expression could correlate with the low number of COVID-19-attributable
167 deaths seen in Japan as compared to other industrialized countries (22).

168 **4. Conclusion**

169 Findings in this study demonstrate how variations in Host Human Leukocyte Antigen
170 (HLA) gene expression can influence the antigenic presentation of coronavirus epitopes. We
171 identified phosphorylation sites in close proximity to the 203/204: RG>KR mutation and
172 modeled the mutation's potential role in the alteration of protein structure and favorable
173 electrostatic interaction between positively charged Arg and the negatively charged P-

174 Ser202/205. Major MHC-I molecules play a key role in the recognition of intracellular pathogens.
175 Low HLA-A*68:01 expression could correlate with the low number of COVID-19-attributable
176 deaths seen in Japan as compared to other industrialized countries. Importantly, we found that
177 RG>KR mutated SARS-CoV-2 expands the ability for differential expression of the N protein
178 epitope on Major Histocompatibility Complexes (MHC) of varying Human Leukocyte Antigen
179 (HLA) origin.

180 **5. Methods**

181 *5.1. Data retrieval and sequence alignment*

182 We used BLASTP programs from the NCBI database search (23) to find the LKR N-
183 protein sequence (43 nucleotides long) of all SARS-CoV-2. Conserved and varied residues were
184 identified by using the WebLogo program (24-26). Multiple alignments were performed between
185 full-length N-protein sequences on the EMBL-EBI server. Clustal Omega is used to apply mBed
186 algorithms for guide trees. ClustalW alignment tools executed to output alignment format (27).
187 We analyzed all available sequences available up to September 07th, 2020.

188 *5.2. Structure modeling*

189 The atomic coordinates of the N-terminal domain (NTD) and C-terminal domain (CTD)
190 were obtained from the structure that is available in a Protein Data Bank
191 (<http://www.rcsb.org/pdb>) (PDB ID: 6M3M, 6WZO)(28, 29). The tertiary structure of the full
192 419 a.a. sequencing of N-proteins was predicted using the IntFOLD5 server (PYMOL).
193 Sequences from residues 1-419 for N-protein native Sequence ID: YP_009724397.2 and mutant
194 sequence ID: QIQ08827.1 were used in this study. All of the structures were visualized using

195 PYMOL Chimera software Version 1.7.4 (30). The calculation procedure was almost the same
196 as that in our previous works (31-34).

197 *5.3. Model Validation*

198 ProSA was used to measure the energy distribution of the N-protein structure (35, 36).

199 *5.4. Identification of B-cell epitopes*

200 In this subsection, we used the Immune Epitope Database (IEDB) (36) to determine linear
201 B-cell epitopes operating the incorporated Chou & Fasman Beta-Turn prediction module (37).
202 We supplied the FASTA sequence of the targeted protein as an input considering all default
203 parameters. We also used the Discotope 2.0 (38) method to predict epitopes based on N-protein
204 conformation and residue exposure.

205 *5.5. Identification of T-cell epitopes*

206 We used the TepiTool, a T cell Epitope Tool that is used for MHC class I and II binding
207 predictions. The IEDB team's recommendations were selected as defaults to automatically select
208 the top peptides (39). In the MHC-I Binding Prediction feature, the default value provided is 1.0,
209 i.e. all peptides with percentile rank ≤ 1.0 will be selected as predicted peptides. The list of
210 representative alleles from different HLA supertypes was selected by the panel of 27 allele
211 reference sets. The peptide selection criterion in this approach will always be predicted percentile
212 rank. MHC-II binding prediction Results from the default value provided is 10.0, i.e. all peptides
213 with percentile rank ≤ 10.0 will be selected as predicted peptides by using the panel of 26 most
214 frequent alleles.

215 *5.6. Prediction of protein subcellular localization using deep learning*

216 The subcellular localization of wild and mutant N proteins was predicted using DeepLoc-
217 1.0 software (40). Using the 419 sequence number at residues 203/204, a.a. of wild/ mutant
218 strains were used to provide information about the subcellular localization of eukaryotic proteins
219 using Neural Networks algorithm trained.

220 References

- 221 1. Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, Duan G. 2020. Virology, Epidemiology,
222 Pathogenesis, and Control of COVID-19. *Viruses* 12.
- 223 2. Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, Ippolito G, McHugh TD, Memish ZA,
224 Drosten C, Zumla A, Petersen E. 2020. The continuing 2019-nCoV epidemic threat of novel
225 coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China.
226 *International journal of infectious diseases : IJID : official publication of the International Society
227 for Infectious Diseases* 91:264-266.
- 228 3. Carlos WG, Dela Cruz CS, Cao B, Pasnick S, Jamil S. 2020. Novel Wuhan (2019-nCoV)
229 Coronavirus. *Am J Respir Crit Care Med* 201:P7-p8.
- 230 4. Wang W, Zhang W, Zhang J, He J, Zhu F. 2020. Distribution of HLA allele frequencies in 82
231 Chinese individuals with coronavirus disease-2019 (COVID-19). *Hla* 96:194-196.
- 232 5. Nguyen A, David JK, Maden SK, Wood MA, Weeder BR, Nellore A, Thompson RF. 2020. Human
233 Leukocyte Antigen Susceptibility Map for Severe Acute Respiratory Syndrome Coronavirus 2. *J
234 Virol* 94.
- 235 6. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. 2016. Coronaviruses - drug discovery and
236 therapeutic options. *Nat Rev Drug Discov* 15:327-47.
- 237 7. Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, Liu W, Bi Y, Gao GF. 2016. Epidemiology, Genetic
238 Recombination, and Pathogenesis of Coronaviruses. *Trends Microbiol* 24:490-502.
- 239 8. Ren AX, Xie YH, Kong YY, Yang GZ, Zhang YZ, Wang Y, Wu XF. 2004. Expression, purification
240 and sublocalization of SARS-CoV nucleocapsid protein in insect cells. *Acta Biochim Biophys Sin
241 (Shanghai)* 36:754-8.
- 242 9. Macneughton MR, Davies HA. 1978. Ribonucleoprotein-like structures from coronavirus particles.
243 *J Gen Virol* 39:545-9.
- 244 10. Franco-Muñoz C, Álvarez-Díaz DA, Laiton-Donato K, Wiesner M, Escandón P, Usme-Ciro JA,
245 Franco-Sierra ND, Flórez-Sánchez AC, Gómez-Rangel S, Rodríguez-Calderon LD, Barbosa-
246 Ramirez J, Ospitia-Baez E, Walteros DM, Ospina-Martinez ML, Mercado-Reyes M. 2020.
247 Substitutions in Spike and Nucleocapsid proteins of SARS-CoV-2 circulating in South America.
248 *Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in
249 infectious diseases* 85:104557-104557.
- 250 11. Chang C-k, Hou M-H, Chang C-F, Hsiao C-D, Huang T-h. 2014. The SARS coronavirus
251 nucleocapsid protein--forms and functions. *Antiviral research* 103:39-50.
- 252 12. Luo H, Chen J, Chen K, Shen X, Jiang H. 2006. Carboxyl terminus of severe acute respiratory
253 syndrome coronavirus nucleocapsid protein: self-association analysis and nucleic acid binding
254 characterization. *Biochemistry* 45:11827-35.
- 255 13. He R, Dobie F, Ballantine M, Leeson A, Li Y, Bastien N, Cutts T, Andonov A, Cao J, Booth TF,
256 Plummer FA, Tyler S, Baker L, Li X. 2004. Analysis of multimerization of the SARS coronavirus
257 nucleocapsid protein. *Biochemical and biophysical research communications* 316:476-483.
- 258 14. Okada M, Takemoto Y, Okuno Y, Hashimoto S, Yoshida S, Fukunaga Y, Tanaka T, Kita Y,
259 Kuwayama S, Muraki Y, Kanamaru N, Takai H, Okada C, Sakaguchi Y, Furukawa I, Yamada K,

- 260 Matsumoto M, Kase T, Demello DE, Peiris JS, Chen PJ, Yamamoto N, Yoshinaka Y, Nomura T,
261 Ishida I, Morikawa S, Tashiro M, Sakatani M. 2005. The development of vaccines against SARS
262 corona virus in mice and SCID-PBL/hu mice. *Vaccine* 23:2269-72.
- 263 15. Gao W, Tamin A, Soloff A, D'Aiuto L, Nwanegbo E, Robbins PD, Bellini WJ, Barratt-Boyes S,
264 Gambotto A. 2003. Effects of a SARS-associated coronavirus vaccine in monkeys. *Lancet*
265 362:1895-6.
- 266 16. Dean L. 2012. Carbamazepine Therapy and HLA Genotype. *In* Pratt VM, Scott SA, Pirmohamed
267 M, Esquivel B, Kane MS, Kattman BL, Malheiro AJ (ed), *Medical Genetics Summaries*. National
268 Center for Biotechnology Information (US), Bethesda (MD).
- 269 17. Hertz T, Oshansky CM, Roddam PL, DeVincenzo JP, Caniza MA, Jojic N, Mallal S, Phillips E,
270 James I, Halloran ME, Thomas PG, Corey L. 2013. HLA targeting efficiency correlates with
271 human T-cell response magnitude and with mortality from influenza A infection. *Proc Natl Acad*
272 *Sci U S A* 110:13492-7.
- 273 18. Grant E, Wu C, Chan KF, Eckle S, Bharadwaj M, Zou QM, Kedzierska K, Chen W. 2013.
274 Nucleoprotein of influenza A virus is a major target of immunodominant CD8⁺ T-cell responses.
275 *Immunol Cell Biol* 91:184-94.
- 276 19. Middleton D, Menchaca L, Rood H, Komerofsky R. 2003. New allele frequency database:
277 <http://www.allelefrequencys.net>. *Tissue Antigens* 61:403-7.
- 278 20. Clemens EB, Grant EJ, Wang Z, Gras S, Tipping P, Rossjohn J, Miller A, Tong SYC, Kedzierska
279 K. 2016. Towards identification of immune and genetic correlates of severe influenza disease in
280 Indigenous Australians. *Immunology and cell biology* 94:367-377.
- 281 21. Burki T. 2020. COVID-19 in Latin America. *The Lancet Infectious diseases* 20:547-548.
- 282 22. Iwasaki A, Grubaugh ND. 2020. Why does Japan have so few cases of COVID-19? *EMBO*
283 *molecular medicine* 12:e12481-e12481.
- 284 23. Crooks GE, Hon G, Chandonia JM, Brenner SE. 2004. WebLogo: a sequence logo generator.
285 *Genome Res* 14:1188-90.
- 286 24. Vahed M, Ishihara J-I, Takahashi H. 2019. DPartite: A tool for detecting bipartite motifs by
287 considering base interdependencies. *PloS one* 14:e0220207-e0220207.
- 288 25. Schneider TD, Stephens RM. 1990. Sequence logos: a new way to display consensus sequences.
289 *Nucleic acids research* 18:6097-6100.
- 290 26. Madeira F, Park YM, Lee J, Buso N, Gur T, Madhusoodanan N, Basutkar P, Tivey ARN, Potter
291 SC, Finn RD, Lopez R. 2019. The EMBL-EBI search and sequence analysis tools APIs in 2019.
292 *Nucleic Acids Res* 47:W636-w641.
- 293 27. Kang S, Yang M, Hong Z, Zhang L, Huang Z, Chen X, He S, Zhou Z, Zhou Z, Chen Q, Yan Y,
294 Zhang C, Shan H, Chen S. 2020. Crystal structure of SARS-CoV-2 nucleocapsid protein RNA
295 binding domain reveals potential unique drug targeting sites. *Acta Pharm Sin B* 10:1228-1238.
- 296 28. Ye Q, West AMV, Silletti S, Corbett KD. 2020. Architecture and self-assembly of the SARS-CoV-
297 2 nucleocapsid protein. *bioRxiv* doi:10.1101/2020.05.17.100685:2020.05.17.100685.
- 298 29. McGuffin LJ, Adiyaman R, Maghrabi AHA, Shuid AN, Brackenridge DA, Nealon JO, Philomina
299 LS. 2019. IntFOLD: an integrated web resource for high performance protein structure and
300 function prediction. *Nucleic Acids Res* 47:W408-w413.
- 301 30. Vahed M, Vahed M, Sweeney A, Shirazi FH, Mirsaiedi M. 2020. Mutation in position of 32
302 (G>U) of S2M differentiate human SARS-CoV2 from Bat Coronavirus. *bioRxiv*
303 doi:10.1101/2020.09.02.280529:2020.09.02.280529.
- 304 31. Wiederstein M, Sippl MJ. 2007. ProSA-web: interactive web service for the recognition of errors
305 in three-dimensional structures of proteins. *Nucleic Acids Res* 35:W407-10.
- 306 32. Vahed M, Sweeney A, Shirasawa H, Vahed M. 2019. The initial stage of structural transformation
307 of Aβ(42) peptides from the human and mole rat in the presence of Fe(2+) and Fe(3+): Related to
308 Alzheimer's disease. *Comput Biol Chem* 83:107128.
- 309 33. Vahed M, Neya S, Matsuzaki K, Hoshino T. 2018. Simulation Study on Complex Conformations
310 of Aβ(42) Peptides on a GM1 Ganglioside-Containing Lipid Membrane. *Chem Pharm Bull*
311 (Tokyo) 66:170-177.

- 312 34. Vahed M, Ahmadian G, Ameri N, Vahed M. 2019. G-rich VEGF aptamer as a potential inhibitor
313 of chitin trafficking signal in emerging opportunistic yeast infection. *Comput Biol Chem* 80:168-
314 176.
- 315 35. Sippl MJ. 1993. Recognition of errors in three-dimensional structures of proteins. *Proteins* 17:355-
316 62.
- 317 36. Kim Y, Ponomarenko J, Zhu Z, Tamang D, Wang P, Greenbaum J, Lundegaard C, Sette A, Lund
318 O, Bourne PE, Nielsen M, Peters B. 2012. Immune epitope database analysis resource. *Nucleic
319 Acids Research* 40:W525-W530.
- 320 37. Chou PY, Fasman GD. 1978. Prediction of the secondary structure of proteins from their amino
321 acid sequence. *Adv Enzymol Relat Areas Mol Biol* 47:45-148.
- 322 38. Krangelum JV, Lundegaard C, Lund O, Nielsen M. 2012. Reliable B cell epitope predictions:
323 impacts of method development and improved benchmarking. *PLoS Comput Biol* 8:e1002829.
- 324 39. Paul S, Sidney J, Sette A, Peters B. 2016. TepiTool: A Pipeline for Computational Prediction of T
325 Cell Epitope Candidates. *Curr Protoc Immunol* 114:18.19.1-18.19.24.
- 326 40. Almagro Armenteros JJ, Sønderby CK, Sønderby SK, Nielsen H, Winther O. 2017. DeepLoc:
327 prediction of protein subcellular localization using deep learning. *Bioinformatics* 33:3387-3395.

328

329

330

331

332

333

334

335

336

337

338

339

340

341 **Figures and Tables**

CLUSTAL O(1.2.4) multiple sequence alignment

```

MERS-COVS:      QSSSRASSVSRNSSRSSSQGSRSGNSTRGTSFPGPSGIGAVGGDLLYLDLLNRIQALESGK 60
SARS-COV-1:    QASSRSSSRSRGNSRNSTPGSSRGNSPAM---ASGGGETALALLLLDRLNQLESKVSQK 57
Bat-covs:      QASSRSSSRSRNSSRNSTPGSSRGTS PAM---AGNGSDAALALLLLDRLNQLESKMSGK 57
SARS-COV-2*:  QASSRSSSRSRNSSRNSTPGSSKRTS PAM---AGNGGDAALALLLLDRLNQLESKMSGK 57
SARS-COV-2:   QASSRSSSRSRNSSRNSTPGSSRGTS PAM---AGNGGDAALALLLLDRLNQLESKMSGK 57
Pangolin:      QASSRSSSRSRNSSRNITPGSSRGTS PAM---AGNGGDAALALLLLDRLNQLESKMSGK 57
                *:****:* *_.**.: : *  _*      .. . . . * * * * *: : ***
    
```

```

MERS-COVS:      VKQSQPKVIK 71
SARS-COV-1:    GQQQQGQTVK 68
Bat-covs:      GQQQQSQTVK 68
SARS-COV-2*:  GQQQQGQTVK 68
SARS-COV-2:   GQQQQGQTVK 68
Pangolin:      GQQQQGQTVK 68
                :*.* :.:**
    
```



342

343

344 **Figure. 1.** Coronavirus N-protein LKR sequence domains. (a) Alignment for bat coronavirus
345 pangolin, SARS-CoV, SARS-CoV-2 and SARS-CoV2n each genotype for sequence
346 representation. Columns with changes for nucleotide positions have been color-coded. (b)
347 ClustalW multiple sequence alignment trees display of coronavirus. (*)The asterisk indicates the
348 mutation type.

349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376






Figure 2. (a) Schematic representation of the N protein LKR domain, (b) Multiple sequence alignment logos of selected N protein LKR domain, a.a. letter heights indicate their frequency at the position 203/204 in SARS-COV-2. (c) The SARS-CoV-2 N protein conserved mutations at the position 203/204 in a phylogenetic graph obtained from Nextstrain database. Picture captured date: 9/25/2020.




377

378 **Figure 3.** Three structure dimensional depicted of the based on the energy values where “blue”
379 represents lowest energy and “red” represents highest energy in the N-protein (a) SARS-CoV-2
380 wild (b) SARS-CoV-2 mutant. (c) ProSa energy plots of N-protein wild type a.a. 203/204 RG
381 (d) mutant type a.a. 203/204 KR.




382

383 **Figure 4.** ProSa Phosphorylation plots of N-protein. (a) Phosphorylation sites predicted in the
 384 local LKR SARS-CoV-2 wild (b) phosphorylation score and substrates of kinases SARS-CoV-
 385 2 wild (c) Phosphorylation sites predicted in the local LKR SARS-CoV-2 mutant.(d)
 386 phosphorylation score and substrates of kinases SARS-CoV-2 mutant.



387

388 **Figure. 5** Schematic representation of the mutation and possibility electrostatic interactions
389 between positively charged Arg/Lys and the negatively charged P-Ser/Thr as shown yellow
390 dotted lines. (a) the wild type SARS-CoV-2 N-protein with Arg and Gly at position 203 and 204,
391 respectively (b) the variant SARS-CoV-2 N-protein with mutations at position 203 and 204
392 (203R>K, 204G>R). These residues are colour-coded based on their Charges (Green: positively
393 charged, Purple: negatively charged P-Ser/Thr). The phosphate groups on Ser/Thr residues at
394 position 202, 205 and 206 are denoted as red circles on yellow sticks




413 **Figure 6.** Hierarchical tree-predicted subcellular localizations of N-protein using neural
414 networks algorithm. (a) Wild (203R),(204G). (b) Mutant (203K),(204R). (c) N-protein residue
415 position prediction Wild (203K),(204R). (d) N-protein residue position prediction Mutant
416 (203K), (204R)

417


418

419

(a) Wild



(b) Mutant R203K



(c) Mutant G204R




Figure 6. Graphical representation of prediction linear B-cell epitopes within the N-protein of (a) SARS-COV-2 wild (b) SARS-COV-2 R203K mutant (c) G203R by IEDB scales. Arrow depicts the residue 204.

Table 1. SARS-CoV-2 Wild

Gene Position	Epitope	*HLA Class I Population Presentation	HLA Class I		HLA Class II Population Presentation	HLA Class II		Dissimilarity Score	Conservation	Combined T Cell Score	B and T Cell	
			Alleles	HLA Class I Bound Binders		Alleles	HLA Class II Bound Binders				Total Score	Total Percentile
NP_LKR	QASSRSSRSRN SSRNSTPGSSRG TSPARMAGNGG DAALALLLDRLN QLESKMSGKGQQ QQGQTVTK	18.38% South America 15.13% Japan 8.61% Iran Persian	8	HLA-A: 02:01, 02:03, 02:06, 30:01, 51:01, 11:01, 31:01, HLA-B: 08:01, HLA-C: 03:03	N/A	15	HLA-DRB: DRB4*01:01, DPA1*03:01/DPB1*04:02 DRB3*01:01, DQA1*01:02/DQB1*06:02 DRB1*03:01 DRB1*11:01 DPA1*02:01/DPB1*01:01 DRB1*12:01 DQA1*04:01/DQB1*04:02 DPA1*02:01/DPB1*05:01 DQA1*03:01/DQB1*03:02 DRB1*04:01 DPA1*01:03/DPB1*02:01 DRB1*15:01 DRB1*08:02	N/A	79.08%	0.16	N/A	N/A

Read theme colors depicted epitope in the region target 203-204.

*Asterisk depicted that only the epitope in the area 203-204 is included in the calculation.

N-KKR: N protein linkage

449

450 **Table 1:** SARS-CoV-2 wild type N protein T cell HLA epitope predictions at gene position
 451 NP_LKR. HLA-class I binders depicted in red included only the epitope in the target region 203-
 452 204 in the calculation. Frequency of HLA class I representation within South American, Japanese,
 453 and Iranian populations is recorded as a frequency.

454

455

Table 2. SARS-CoV-2 Mutant

Gene Position	Epitope	HLA Class I			HLA Class II			Dissimilarity Score	Conservation	Combined Cell Score	B and T Cell	
		Population Presentation	Alleles Bound	HLA Class I Binders	Population Presentation	Alleles Bound	HLA Class II Binders				Total Score	Total Percentile
NP_LKR	QASSRSSRSRN SSRNSTPGSSKR TSPARMAGNGG DAALALLLDRLN QLESKMSGKGQQ QQGQTVTK	28.25% South America 19.81% Japan 9.75% Iran Persian	40	HLA-A: 02:01, 02:03, 08:01, 02:06, 31:01, 30:01, 68:01, 11:01 HLA-B: 51:01, HLA-C: 03:03	N/A	15	HLA-DRB: DRB4*01:01, DPA1*03:01/DPB1*04:02 DRB3*01:01, DQA1*01:02/DQB1*06:02 DRB1*03:01 DRB1*11:01 DPA1*02:01/DPB1*01:01 DRB1*12:01 DQA1*04:01/DQB1*04:02 DPA1*02:01/DPB1*05:01 DQA1*03:01/DQB1*03:02 DRB1*04:01 DPA1*01:03/DPB1*02:01 DRB1*15:01 DRB1*08:02	N/A	13.63%	0.15	N/A	N/A

Read theme colors depicted epitope in the region target 203-204.

*Asterisk depicted that only the epitope in the area 203-204 is included in the calculation.

N-KKR: N protein linkage

456

457 **Table 2:** SARS-CoV-2 mutant G204R type N protein T cell HLA epitope predictions at gene
 458 position NP_LKR. HLA-class I binders depicted in red included only the epitope in the target
 459 region 203-204 in the calculation. Frequency of HLA class I representation within South American,
 460 Japanese, and Iranian populations is recorded as a frequency.

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520